anticoagulant medication

"It was also unreasonable that she was not scanned in the emergency department before she was discharged, given her reduced level of consciousness and confusion; her headache; and the fact that she was on anticoagulant medication (medication to prevent blood clots).

Shurgers et al end their paper on a positive note in relation with the use of MK-7 with patients on anticoagulant medication:

Anticoagulant medication use at the therapeutic doses does not cause hematuria, thus, urologic problems should be investigated for hematuria etiology in these patients (12,15).

However, the researchers discovered that taking anticoagulant medication to help prevent blood clots was linked with a decrease in the risk of dementia.

According to previous studies, oral surgical and clinical approach to the patients who take anticoagulant medication made it necessary to stop the anticoagulant treatment for several days or reduce the dose of anticoagulant drug for preventing severe life-threatening hemorrhage (7).

Medisafe will offer access within the overall Medisafe app to a section with educational materials specific to Pradaxa including health literacy videos, relevant health tips and a Pradaxa Savings Card to certain individuals who are taking Pradaxa (dabigatran etexilate mesylate), an anticoagulant medication.

Currently, patients who take oral anticoagulant medication for the treatment of thrombosis or prophylaxis can benefit from anticoagulant reversal medications when they have a life-threatening bleed or they need an urgent surgical intervention.

UAE residents who take anticoagulant medication, be warned.

Findings on anticoagulant medication and risk of complications in patients taking VKAs are mixed.

Anticoagulant medication can help stop further clots forming.

Patient had history of bilateral deep venous thrombosis and taking anticoagulant medication. His physical examination revealed a pulsatile mass at his left wrist concurrently.

Treatment of the patients: After confirmation of no bleeding or low density shadow by cranial CT, normal blood routines, no previous history of blood disorder or oral anticoagulant medication, or no serious history of hepatonephric disease, the patients in group A were given 0.6-0.7 mg/kg rt-PA and <30 minutes-DNT for the thrombolytic therapy without considering the results of blood clotting and hepatonephric function assay; the patients in group B were given 0.6-0.7 mg/kg rt-PA and 60-min DNT after received normal results of blood clotting and hepatonephric function assay; the patients in group C were given 0.9 mg/kg rt-PA and 60-min DNT after received normal results of blood clotting and hepatonephric function assay.